aPC-PAR-3 signaling protects against podocyte injury and proteinuria in vivo. (A) Bar graph summarizing proteinuria levels (milligrams per milliliter) in urine obtained 24 hours after LPS treatment. Loss of PAR-3 (PAR-3^−/− mice) or blocking PAR-1 (P1pal-12S) reduces aPCs' protective effect. (B) Representative immunoblot and bar graph showing nephrin levels analyzed from renal cortex samples in LPS-treated mice, illustrating the failure of aPCs to maintain nephrin expression in PAR3^−/− or P1pasl-12S–treated mice. Ppal-12S indicates PAR-1 antagonist. Data are mean ± SEM of at least 6 animals per group. *P < .05 vs control or LPS + aPC-treated (ANOVA).